Andere Sprachen Legend Biotech Corporation

Aktien

A2P5AH

US52490G1022

LEGN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
44.42 ^USD	-1.66%		-5.73%	-26.18%

22.04.	CARVYKTI® (ciltacabtagene autoleucel) von Legend Biotech Corporation von der Europäischen Kommission für die Zweitlinienbehandlung von Patienten mit rezidiviertem und refraktärem Multiplem Myelom zugelassen	CI
17.04.	LEGEND BIOTECH CORPORATION : Von Scotiabank zum Kauf angehoben	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	23.04.
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	22.04.
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	22.04.
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	22.04.
US FDA mandates label updates on CAR-T cancer therapies	19.04.
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug	17.04.
Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended March 31, 2024 - Form 6-K	16.04.
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results	11.04.
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval	09.04.
Innovative personalised immunotherapy approved for multiple myeloma	08.04.
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	08.04.
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma	08.04.
U.S. FDA approves expanded use of J&J's cancer cell therapy	06.04.
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma	06.04.
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma	06.04.
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	05.04.
U.S. FDA allows expanded use of Bristol Myers' cell therapy	05.04.
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance Report	20.03.
Legend Biotech Files Mixed-Securities Shelf Registration	19.03.
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report	19.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Legend Biotech Corporation

Aktien

A2P5AH

US52490G1022

LEGN

Andere Sprachen

Filter